SCHEMBL13991913

SCHEMBL13991913

CCC(=O)C(=O)NCCCCC(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 3/20 0.49
▸ PLA2G2A P14555 2/20 0.44
▸ TDP1 Q9NUW8 1/20 0.42
▸ PLA2G4A P47712 1/20 0.41
▸ MAOA P21397 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ CA12 O43570 3/20 0.36
▸ CA1 P00915 3/20 0.36
▸ CA2 P00918 3/20 0.36
▸ CA9 Q16790 3/20 0.36
▸ ALDH1A1 P00352 1/20 0.34
▸ TPSAB1 Q15661 1/20 0.34
▸ TPSD1 Q9BZJ3 1/20 0.34
▸ TPSG1 Q9NRR2 1/20 0.34
▸ FPR3 P25089 1/20 0.34
▸ FPR2 P25090 1/20 0.34
▸ CA14 Q9ULX7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13991880 0.95 EPHX2 (0.44) EPHX2PLA2G2ATDP1PLA2G4AMAOA
SCHEMBL13991916 0.88 MLYCD (0.39) EPHX2PLA2G2ATDP1PLA2G4AMAOA
SCHEMBL806270 0.82 MEN1 (0.57) EPHX2TDP1MAOAMAOBMEN1
SCHEMBL2608185 0.81 EPHX2 (0.49) EPHX2PLA2G2ATDP1MAOAMAOB
SCHEMBL13991911 0.80 ALDH1A1 (0.51) EPHX2PLA2G2APLA2G4AGAAALDH1A1
SCHEMBL16349624 0.80 TDP1 (0.66) EPHX2TDP1MAOAMAOBMEN1
SCHEMBL2608202 0.79 EPHX2 (0.51) EPHX2PLA2G2ATDP1MAOAMAOB
SCHEMBL13991915 0.79 TET2 (0.41) PLA2G2ATDP1MAOAMAOBMEN1
SCHEMBL25942884 0.78 TDP1 (0.69) EPHX2TDP1MAOAMAOBMEN1
SCHEMBL13991902 0.78 EPHX2 (0.39) EPHX2PLA2G2ATDP1PLA2G4AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080319065-A1 Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2008-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319065-A1 Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release PLA2G4A, PLA2G4B, PLA2G2A EPHX2 140/4885PLA2G2A 3/4885TDP1 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback